BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15633216)

  • 1. Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2.
    Huang DS; Shen KZ; Wei JF; Liang TB; Zheng SS; Xie HY
    World J Gastroenterol; 2005 Jan; 11(2):204-7. PubMed ID: 15633216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.
    Cheng AS; Chan HL; Leung WK; Wong N; Johnson PJ; Sung JJ
    Int J Oncol; 2003 Jul; 23(1):113-9. PubMed ID: 12792783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor.
    Moalic S; Liagre B; Le Bail JC; Beneytout JL
    Int J Oncol; 2001 Mar; 18(3):533-40. PubMed ID: 11179483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines.
    Cheng J; Imanishi H; Amuro Y; Hada T
    Int J Cancer; 2002 Jun; 99(5):755-61. PubMed ID: 12115513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
    Hu KQ; Yu CH; Mineyama Y; McCracken JD; Hillebrand DJ; Hasan M
    Int J Oncol; 2003 Apr; 22(4):757-63. PubMed ID: 12632065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.
    Schmidt CM; Wang Y; Wiesenauer C
    J Gastrointest Surg; 2003 Dec; 7(8):1024-33. PubMed ID: 14675712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of NS-398 on cyclooxygenase-2 expression and proliferation of HepG2 cells].
    Wu Q; Chang W; Zhu CC; Fan LR; Song SZ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2008 Apr; 42(4):260-3. PubMed ID: 18763637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.
    Liu XH; Yao S; Kirschenbaum A; Levine AC
    Cancer Res; 1998 Oct; 58(19):4245-9. PubMed ID: 9766645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: an experimental study].
    Zhang YC; Wang S; Zhang H; Ye YJ; Liang B; Cui ZR
    Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):583-6. PubMed ID: 15144595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms involved in the antiproliferative effect of two COX-2 inhibitors, nimesulide and NS-398, on colorectal cancer cell lines.
    Buecher B; Broquet A; Bouancheau D; Heymann MF; Jany A; Denis MG; Bonnet C; Galmiche JP; Blottière HM
    Dig Liver Dis; 2003 Aug; 35(8):557-65. PubMed ID: 14567460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells.
    Michael MS; Badr MZ; Badawi AF
    Int J Mol Med; 2003 Jun; 11(6):733-6. PubMed ID: 12736714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
    Li J; Chen X; Dong X; Xu Z; Jiang H; Sun X
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1814-20. PubMed ID: 17074019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21.
    Toyoshima T; Kamijo R; Takizawa K; Sumitani K; Ito D; Nagumo M
    Br J Cancer; 2002 Apr; 86(7):1150-6. PubMed ID: 11953864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective cyclooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line.
    Yamashita H; Osaki M; Honjo S; Yoshida H; Teshima R; Ito H
    Anticancer Res; 2003; 23(6C):4671-6. PubMed ID: 14981912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
    Ding XZ; Tong WG; Adrian TE
    Anticancer Res; 2000; 20(4):2625-31. PubMed ID: 10953335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells.
    Kase S; Osaki M; Honjo S; Takeda A; Adachi K; Araki K; Ito H
    J Exp Clin Cancer Res; 2004 Jun; 23(2):301-7. PubMed ID: 15354416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway.
    Zhang M; Abe Y; Matsushima T; Nishimura J; Nawata H; Muta K
    Leuk Lymphoma; 2005 Mar; 46(3):425-33. PubMed ID: 15621834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
    J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive expression of the cyclooxygenase-2 gene in T-cell lines infected with human T cell leukemia virus type I.
    Mori N; Inoue H; Yoshida T; Tanabe T; Yamamoto N
    Int J Cancer; 2001 Dec; 94(6):813-9. PubMed ID: 11745483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
    Li S; Tong Q; Zhang W; Wang Q; Chen Z; Wu Q
    Cancer Invest; 2008 May; 26(4):333-7. PubMed ID: 18443952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.